Ettingshausen CE - Search Results

1

Role of von Willebrand factor in immune tolerance induction.

Ettingshausen CE, Kreuz W. Ettingshausen CE, et al. Blood Coagul Fibrinolysis. 2005 Apr;16 Suppl 1:S27-31. doi: 10.1097/01.mbc.0000167660.30886.e9. Blood Coagul Fibrinolysis. 2005. PMID: 15849524 Review.

2

Neonatal sepsis: a challenge in hemostaseology.

Kreuz W, Veldmann A, Fischer D, Schlösser R, Volk WR, Ettingshausen CE. Kreuz W, et al. Among authors: ettingshausen ce. Semin Thromb Hemost. 1999;25(6):531-5. doi: 10.1055/s-2007-994961. Semin Thromb Hemost. 1999. PMID: 10632474 Review.

3

Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans.

Ettingshausen CE, Veldmann A, Beeg T, Schneider W, Jäger G, Kreuz W. Ettingshausen CE, et al. Semin Thromb Hemost. 1999;25(6):537-41. doi: 10.1055/s-2007-994962. Semin Thromb Hemost. 1999. PMID: 10632475 Clinical Trial.

4

Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding--successful thrombolysis under heparin therapy.

Ettingshausen CE, Saguer IM, Kreuz W. Ettingshausen CE, et al. Eur J Pediatr. 1999 Dec;158 Suppl 3:S180-2. doi: 10.1007/pl00014351. Eur J Pediatr. 1999. PMID: 10650865

5

Is recombinant tissue plasminogen activator an option in the treatment of meningococcus-induced purpura?

Veldman A, Ehrenberg A, Jäger G, Ettingshausen CE, Schneider W, Kreuz W. Veldman A, et al. Among authors: ettingshausen ce. Crit Care Med. 2000 Feb;28(2):598-600. doi: 10.1097/00003246-200002000-00066. Crit Care Med. 2000. PMID: 10708220 No abstract available.

6

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.

Kreuz W, Ettingshausen CE, Zyschka A, Oldenburg J, Saguer IM, Ehrenforth S, Klingebiel T. Kreuz W, et al. Among authors: ettingshausen ce. Semin Thromb Hemost. 2002 Jun;28(3):285-90. doi: 10.1055/s-2002-32664. Semin Thromb Hemost. 2002. PMID: 12098090

7

Epidemiology of inhibitors and current treatment strategies.

Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T; GTH PUP Study Group. Kreuz W, et al. Among authors: ettingshausen ce. Haematologica. 2003 Jun;88(6):EREP04. Haematologica. 2003. PMID: 12826530 Review.

8

Long-term aspects of hemophilia B treatment: part I-role for prophylaxis.

Ettingshausen CE, Kreuz W. Ettingshausen CE, et al. Blood Coagul Fibrinolysis. 2004 Jun;15 Suppl 2:S11-3. doi: 10.1097/00001721-200406002-00004. Blood Coagul Fibrinolysis. 2004. PMID: 15322452 Review.

9

Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.

Ettingshausen CE, Kreuz W. Ettingshausen CE, et al. Haemophilia. 2006 Dec;12 Suppl 6:102-6. doi: 10.1111/j.1365-2516.2006.01373.x. Haemophilia. 2006. PMID: 17123402 Review.

10

Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys.

Kurnik K, Kreuz W, Horneff S, Düring C, Schobess R, Bidlingmaier C, Ettingshausen CE, Krümpel A, Bogdanova N, Nowak-Göttl U. Kurnik K, et al. Among authors: ettingshausen ce. Haematologica. 2007 Jul;92(7):982-5. doi: 10.3324/haematol.11161. Haematologica. 2007. PMID: 17606451 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page